)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Kezar Life Sciences (KZR) investor relations material
Kezar Life Sciences Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Focused on developing zetomipzomib for autoimmune hepatitis after terminating other clinical programs, with ongoing regulatory engagement following FDA removal of a clinical hold on a key trial in July 2025.
Type C meeting with FDA requested for Q4 2025 to discuss registration-enabling trial design.
PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting 2025.
Zung To promoted to Chief Development Officer, strengthening clinical development leadership.
No product sales to date; operations funded by equity, debt, and a collaboration with Everest Medicines, with continued significant operating losses expected.
Financial highlights
Net loss for Q2 2025 was $13.7 million, down from $21.5 million in Q2 2024; six-month net loss was $30.3 million, down from $43.2 million year-over-year.
Operating expenses for Q2 2025 were $14.6 million, a decrease from $23.4 million in Q2 2024, mainly due to lower R&D and restructuring costs.
Cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million at December 31, 2024.
R&D expenses for Q2 2025 decreased to $9.6 million from $16.3 million in Q2 2024, mainly due to lower clinical activity and personnel costs.
G&A expenses for Q2 2025 decreased to $5.0 million from $5.6 million in Q2 2024.
Outlook and guidance
Cash resources are expected to fund operations for at least 12 months from the reporting date, but additional capital will be needed for long-term plans.
Expenses are expected to remain stable in the near term, then increase as zetomipzomib advances into later-stage development.
On track with clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis.
Type C FDA meeting in Q4 2025 expected to be a key milestone for advancing zetomipzomib.
No revenue from product sales anticipated in the near future; future funding needs depend on clinical progress and regulatory outcomes.
Discuss the plan for zetomipzomib in AIH.
Explain the decrease in R&D expenses.
What is the median duration of response in AIH?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Kezar Life Sciences earnings date
Q3 202511 Nov, 2025
Next Kezar Life Sciences earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Kezar Life Sciences Inc. is a biotechnology company focused on developing therapies for autoimmune diseases and cancer. The company specializes in small-molecule drug candidates targeting protein homeostasis and immune system regulation. Its research and development efforts aim to advance treatments for conditions such as lupus nephritis and other immune-mediated disorders through clinical trials. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage